[go: up one dir, main page]

ES2538486T3 - Preparación de péptidos antigénicos contra el cáncer - Google Patents

Preparación de péptidos antigénicos contra el cáncer Download PDF

Info

Publication number
ES2538486T3
ES2538486T3 ES03795414.6T ES03795414T ES2538486T3 ES 2538486 T3 ES2538486 T3 ES 2538486T3 ES 03795414 T ES03795414 T ES 03795414T ES 2538486 T3 ES2538486 T3 ES 2538486T3
Authority
ES
Spain
Prior art keywords
peptide
preparation
antigenic peptides
against cancer
peptides against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03795414.6T
Other languages
English (en)
Inventor
Haruo Sugiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Institute of Cancer Immunology Inc
Original Assignee
International Institute of Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Institute of Cancer Immunology Inc filed Critical International Institute of Cancer Immunology Inc
Application granted granted Critical
Publication of ES2538486T3 publication Critical patent/ES2538486T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una emulsión de agua-en-aceite que comprende como ingrediente eficaz un péptido que tiene una secuencia de aminoácidos de Cys Tyr Thr Trp Asn Gln Met Asn Leu (SEQ ID NO: 3) que induce CTL que reconoce el péptido WT1 de tipo salvaje de una manera restringida por HLA-A24; en donde la emulsión está en una forma de dosificación unitaria que comprende de 0,1 a 100 mg del péptido.
ES03795414.6T 2002-09-12 2003-09-12 Preparación de péptidos antigénicos contra el cáncer Expired - Lifetime ES2538486T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002266876 2002-09-12
JP2002266876 2002-09-12
PCT/JP2003/011675 WO2004024175A1 (ja) 2002-09-12 2003-09-12 癌抗原ペプチド製剤

Publications (1)

Publication Number Publication Date
ES2538486T3 true ES2538486T3 (es) 2015-06-22

Family

ID=31986668

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03795414.6T Expired - Lifetime ES2538486T3 (es) 2002-09-12 2003-09-12 Preparación de péptidos antigénicos contra el cáncer

Country Status (6)

Country Link
US (2) US7342092B2 (es)
EP (1) EP1550453B1 (es)
JP (2) JP4611022B2 (es)
AU (1) AU2003262094A1 (es)
ES (1) ES2538486T3 (es)
WO (1) WO2004024175A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2337743C (en) * 1998-07-31 2015-07-07 Yoshihiro Oka Tumor antigen based on products of the tumor suppressor gene wt1
JP3728439B2 (ja) * 2001-03-22 2005-12-21 治夫 杉山 Ｗｔ１改変ペプチド
ES2538486T3 (es) * 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
ATE538809T1 (de) * 2003-06-27 2012-01-15 Int Inst Cancer Immunology Inc Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff
CA2544214C (en) 2003-11-05 2018-08-28 International Institute Of Cancer Immunology, Inc. Hla-dr-binding antigen peptide derived from wt1
JP4886507B2 (ja) * 2004-03-31 2012-02-29 株式会社癌免疫研究所 Ｗｔ１由来の癌抗原ペプチド
US8178102B2 (en) * 2005-01-19 2012-05-15 Dainippon Sumitomo Pharma Co., Ltd. Emulsified composition for dilution and cancer vaccine composition
ES2523172T3 (es) * 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
EP1951281B1 (en) * 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
CN105315347A (zh) 2005-11-30 2016-02-10 株式会社癌免疫研究所 新型肽化合物
EP2385117B1 (en) * 2006-02-22 2016-07-27 International Institute of Cancer Immunology, Inc. HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
EP2119778B1 (en) 2007-02-27 2015-11-04 International Institute of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
KR101669279B1 (ko) 2007-03-05 2016-10-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
EP2626418B8 (en) 2010-10-05 2021-03-24 International Institute of Cancer Immunology, Inc. Method for activating helper t cell
AU2012276908A1 (en) 2011-06-28 2014-02-20 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
JP6368243B2 (ja) 2011-11-11 2018-08-08 フレッド ハッチンソン キャンサー リサーチ センター がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法
US9492548B2 (en) 2012-12-14 2016-11-15 Intervet Inc. Emulsion containing a non-live medicinal substance
ES2805337T3 (es) 2012-12-17 2021-02-11 Otsuka Pharma Co Ltd Método para activar células T auxiliares
CN107074970B (zh) 2014-08-04 2021-07-30 弗雷德哈钦森癌症研究中心 特异性针对wt-1的t细胞免疫疗法
JP6671141B2 (ja) * 2014-10-21 2020-03-25 大日本住友製薬株式会社 懸濁液剤
JP7393752B2 (ja) * 2018-10-05 2023-12-07 株式会社癌免疫研究所 良性腫瘍の予防または治療薬
CA3132845A1 (en) 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center High avidity wt1 t cell receptors and uses thereof
WO2021034976A1 (en) 2019-08-20 2021-02-25 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for wt-1
CN111333711B (zh) * 2020-03-18 2020-10-09 北京鼎成肽源生物技术有限公司 一种肺癌抗原组合及其应用、细胞毒性t淋巴细胞

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
EP0841068B1 (en) 1995-06-01 2006-07-12 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonucleotide derivative against wilms' tumor gene (wt1)
JPH11513992A (ja) * 1995-12-22 1999-11-30 イースト・カロライナ・ユニバーシティ シチジンデアミナーゼまたはデオキシシチジンデアミナーゼの過剰発現を伴う疾患を治療するための薬剤および方法
US20030092656A1 (en) 1997-07-16 2003-05-15 Haruo Sugiyama Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
CA2337743C (en) 1998-07-31 2015-07-07 Yoshihiro Oka Tumor antigen based on products of the tumor suppressor gene wt1
HK1039782B (en) * 1998-09-30 2008-11-14 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
US20030082194A1 (en) * 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
FR2810888B1 (fr) * 2000-06-29 2004-07-30 Merial Sas Vaccin contre la fievre aphteuse
JP3728439B2 (ja) 2001-03-22 2005-12-21 治夫 杉山 Ｗｔ１改変ペプチド
WO2003028757A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
JPWO2003028758A1 (ja) 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
JP4365784B2 (ja) * 2002-06-12 2009-11-18 株式会社癌免疫研究所 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
ES2538486T3 (es) * 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
JP4480580B2 (ja) * 2002-09-20 2010-06-16 株式会社癌免疫研究所 Ｗｔ１置換型ペプチド
KR20120054644A (ko) * 2003-01-15 2012-05-30 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
ATE538809T1 (de) * 2003-06-27 2012-01-15 Int Inst Cancer Immunology Inc Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff
CA2544214C (en) * 2003-11-05 2018-08-28 International Institute Of Cancer Immunology, Inc. Hla-dr-binding antigen peptide derived from wt1
JP4886507B2 (ja) * 2004-03-31 2012-02-29 株式会社癌免疫研究所 Ｗｔ１由来の癌抗原ペプチド

Also Published As

Publication number Publication date
WO2004024175A1 (ja) 2004-03-25
JP4611022B2 (ja) 2011-01-12
JPWO2004024175A1 (ja) 2006-01-05
JP2009275051A (ja) 2009-11-26
US20070036808A1 (en) 2007-02-15
EP1550453A1 (en) 2005-07-06
US20090263409A1 (en) 2009-10-22
EP1550453B1 (en) 2015-05-27
EP1550453A4 (en) 2009-06-24
AU2003262094A1 (en) 2004-04-30
US7342092B2 (en) 2008-03-11

Similar Documents

Publication Publication Date Title
ES2538486T3 (es) Preparación de péptidos antigénicos contra el cáncer
BR0208183A (pt) Peptìdeo modificado por wt1
PE20121393A1 (es) Analogo peptidico de oxintomodulina
BR0014386A (pt) Composição
EA200901161A1 (ru) Вакцина против гриппа в виде эмульсии типа "масло в воде"
PE20040562A1 (es) Vacunas que comprenden mezclas de cepas meningococicas multivalentes
AR044234A2 (es) Uso de una composicion que comprende oocistos de eimeria vivos
NZ601677A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin d1
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
MX382968B (es) Vacuna de emergencia basada en péptidos sintéticos contra la fiebre aftosa.
SA110310340B1 (ar) تركيبة لعلاج سرطان البروستاتا
EP3501532A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
CO2021017664A2 (es) Péptidos
MY209484A (en) Cpg amphiphiles and uses thereof
AR044236A2 (es) Uso de una composicion que comprende esporozoitos de eimeria vivos
CO2020004801A2 (es) Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares
CR7938A (es) Formulaciones parenterales de peptidos para el tratamiento de lupus eritematoso sistemico
Kalenik et al. Β-defensins–Underestimated peptides in influenza combat
NO20084053L (no) Inhibering av tumorvekst
ES2163631T3 (es) Un peptido mejorado, composicion inmunogenica y vacuna o preparacion medica, un procedimiento para inmunizar a los animales contra la hormona lhrh, analogos del peptido lhrh repetidos en tandem y su uso como vacuna.
Pala et al. Competition between unrelated peptides recognized by H-2-Kd restricted T cells.
BRPI0518571A2 (pt) peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncer
RU2012100241A (ru) Лечение хориоидальной неоваскуляризации с помощью вакцин
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo